Top Markets
Coin of the day
HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS
Classifica tra le azioni #22602
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Prezzo delle azioni
$2.75
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$86.08M
Variazione (1 giorno)
-3.85%
Variazione (1 anno)
-27.06%
Paese
CA
Scambia HLS Therapeutics Inc. (HLS)

Categoria

Cronologia dei frazionamenti azionari per HLS Therapeutics Inc. (HLS)
L’azione HLS Therapeutics Inc. (simbolo: HLS) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 23, 2026.
Una quota di HLS acquistata prima di Aug 23, 2026 equivale oggi a 0 quote di HLS.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti